IPPRA / Grant Monitor

2026-07-07
← Board

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

PAR-25-026 · National Institutes of Health

biomedical clinical public health Health

Closes
2027-01-07 · 184 d
Award ceiling
Award floor
Program funding
Expected awards
Cost sharing
No
Posted
2024-12-05
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

Supports investigator-initiated early-phase Phase I clinical trials of therapeutics and/or diagnostics for heart, lung, blood, and sleep disorders, including required pre-trial preparatory activities directly tied to the intervention.

Funds
evaluation research
University
direct
social behavioral
minor
engineering
minor
life biomedical
central
computational data
minor

⚑ Clinical trial required. · R61/R33 phased, milestone-driven mechanism. · R61 phase supports only final-stage pre-trial activities directly related to the therapeutic/diagnostic intervention (e.g. stability, shipping, site training).

Unit fits — one characterization, each unit's own rules

IPPRA 58 good peripheral portfolio topic: public_health; social/behavioral work is minor; funds evaluation research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Physical Sciences & Engineering (demo) 25 weak technical depth: minor; funds evaluation research (capped)
Tom Love Innovation Hub 15 none deep-tech content; no commercialization signal

Description

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →

Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING